HGSNAT Gene

HGSNAT — Heparan-Alpha-Glucosaminide N-Acetyltransferase

<div class="infobox infobox-gene">
<div class="infobox-header">HGSNAT</div>
<div class="infobox-row"><strong>Gene Symbol:</strong> HGSNAT</div>
<div class="infobox-row"><strong>Full Name:</strong> Heparan-Alpha-Glucosaminide N-Acetyltransferase</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 8p11.21</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 63805</div>
<div class="infobox-row"><strong>OMIM:</strong> 610539</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000145192</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q9Y5S9</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Mucopolysaccharidosis IIIC (Sanfilippo C), Lysosomal Storage Disorders, Neurodegeneration</div>
</div>

Overview

HGSNAT — Heparan-Alpha-Glucosaminide N-Acetyltransferase

<div class="infobox infobox-gene">
<div class="infobox-header">HGSNAT</div>
<div class="infobox-row"><strong>Gene Symbol:</strong> HGSNAT</div>
<div class="infobox-row"><strong>Full Name:</strong> Heparan-Alpha-Glucosaminide N-Acetyltransferase</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 8p11.21</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 63805</div>
<div class="infobox-row"><strong>OMIM:</strong> 610539</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000145192</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q9Y5S9</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Mucopolysaccharidosis IIIC (Sanfilippo C), Lysosomal Storage Disorders, Neurodegeneration</div>
</div>

Overview

HGSNAT (Heparan-Alpha-Glucosaminide N-Acetyltransferase) encodes a lysosomal enzyme that catalyzes a critical step in the degradation of heparan sulfate (HS), a glycosaminoglycan (GAG) component of proteoglycans found on cell surfaces and in the extracellular matrix["@fan2006"]. This enzyme deficiency causes mucopolysaccharidosis type IIIC (MPS IIIC), also known as Sanfilippo syndrome type C, a lysosomal storage disorder characterized by the accumulation of HS in lysosomes throughout the body, particularly in the [central nervous system](/brain-regions/brain)[@valstar2010].

Sanfilippo syndrome represents the most common form of mucopolysaccharidosis affecting the central nervous system, with an estimated incidence of 1 in 70,000 live births. MPS IIIC accounts for approximately 15-20% of all Sanfilippo cases and is caused exclusively by HGSNAT mutations. The disease typically presents in early childhood with progressive neurodevelopmental regression, behavioral problems, and eventually severe intellectual disability. The understanding of HGSNAT function and dysfunction provides insights not only into the pathogenesis of MPS IIIC but also into the broader role of lysosomal function and HS metabolism in neurodegenerative processes that may be relevant to more common conditions like Alzheimer's disease and Parkinson's disease["@cappelluti2019"].

Molecular Biology

Enzyme Function

HGSNAT is a transmembrane enzyme located in the lysosomal membrane that catalyzes the N-acetylation of the terminal alpha-glucosamine residue of heparan sulfate. This enzymatic reaction is essential for the proper degradation of HS through the lysosomal catabolic pathway:

Heparan sulfate (terminal α-GlcN) → HGSNAT → N-acetyl-α-GlcN

The enzyme performs a unique acetylation reaction that converts the terminal glucosamine residue from its deacetylated form to an acetylated form, which is a prerequisite for the subsequent action of α-N-acetylglucosaminidase (NAGLU). Without HGSNAT activity, HS degradation is blocked at this critical step, leading to progressive accumulation of undegraded HS within lysosomes.

Protein Structure

HGSNAT is an 603-amino acid protein with several distinctive features:

| Domain | Position | Function |
|--------|----------|----------|
| Signal peptide | 1-19 | Targets protein to secretory pathway |
| Luminal domain | 20-456 | Contains catalytic site, localizes to lysosome |
| Transmembrane | 457-479 | Anchors enzyme in lysosomal membrane |
| Cytoplasmic tail | 480-603 | Contains trafficking signals |

The enzyme requires proper trafficking to the lysosome for function. This process involves:

• Mannose-6-phosphate receptor-mediated sorting
• Post-translational processing in the Golgi apparatus
• Delivery to late endosomes/lysosomes

Catalytic Mechanism

HGSNAT catalyzes the transfer of an acetyl group from acetyl-CoA to the terminal α-linked glucosamine residue of HS. The reaction requires:

• Substrate: HS with terminal non-acetylated α-glucosamine
• Cofactor: Acetyl-CoA
• Product: HS with terminal N-acetyl-α-glucosamine

Disease Associations

Mucopolysaccharidosis Type IIIC (Sanfilippo C)

MPS IIIC is an autosomal recessive lysosomal storage disorder caused by HGSNAT deficiency[@beesley2011]. The clinical phenotype includes:

Neurological manifestations:

• Progressive intellectual disability
• Behavioral abnormalities (hyperactivity, aggression, sleep disturbances)
• Developmental regression
• Seizures in some patients
• Motor dysfunction (ataxia, spasticity)

• Coarse facial features (milder than other MPS types)
• Short stature
• Thickened skin
• Hepatosplenomegaly
• Recurrent ear and respiratory infections

• Normal early development (first 1-2 years)
• Developmental plateau around age 2-4
• Progressive neurodevelopmental decline
• Severe intellectual disability by age 6-10
• Life expectancy: typically into adolescence or early adulthood

Broader Implications for Neurodegeneration

Beyond its role in MPS IIIC, HGSNAT dysfunction may contribute to more common neurodegenerative diseases[@cappelluti2019]:

Alzheimer's disease:

• HS proteoglycans interact with amyloid-beta and tau
• Altered HS metabolism may affect plaque formation and clearance
• Lysosomal dysfunction is a feature of AD pathology[@choi2019]

• HS is involved in alpha-synuclein aggregation
• Lysosomal dysfunction is central to PD pathogenesis
• HGSNAT expression may be altered in PD brain[@kim2017]

• Connection to broader lysosomal dysfunction
• Insights into cellular clearance mechanisms

Lysosomal Biology and HS Metabolism

The Lysosomal Degradation Pathway

Lysosomal degradation of HS requires the coordinated action of multiple enzymes:

The pathway involves:

• HGSNAT: N-acetylation of terminal α-GlcN
• NAGLU: Removal of N-acetylglucosamine
• HS sulfatases: Removal of sulfate groups
• β-glucuronidase: Cleavage of glucuronic acid linkages

HS in Normal Neural Function

Heparan sulfate plays important roles in normal brain function[@kjellen2018]:

• Synaptic organization: HS proteoglycans (syndecans, glypicans) regulate synaptic development
• Growth factor signaling: HS modulates FGF, VEGF, and BDNF signaling
• Axon guidance: HS regulates netrin and semaphorin signaling
• Blood-brain barrier: HS maintains vascular integrity

Consequences of HS Accumulation

When HGSNAT is deficient, accumulated HS causes:

| Cellular Compartment | Pathological Changes |
|---------------------|---------------------|
| Lysosomes | Enlargement, dysfunction, autofluorescence |
| Cytoplasm | Cellular stress, impaired autophagy |
| Mitochondria | Energy deficit, oxidative stress |
| ER | Unfolded protein response |
| Plasma membrane | Altered receptor signaling |

The accumulated HS disrupts multiple cellular processes, leading to the progressive neurodegeneration seen in MPS IIIC.

Therapeutic Approaches

Enzyme Replacement Therapy (ERT)

ERT for MPS IIIC aims to provide functional HGSNAT to patient cells[@huang2017]:

• Recombinant HGSNAT administration
• Challenges: enzyme cannot cross blood-brain barrier
• Currently limited to peripheral organs
• Investigational approaches for CNS delivery

Gene Therapy

Gene therapy offers the potential for long-term correction[@worthington2017]:

Viral vectors:

• AAV vectors (serotypes crossing blood-brain barrier)
• Lentiviral vectors for ex vivo therapy
• Target neurons and astrocytes

• Intracranial injection
• Intravenous delivery (with cross-BBB vectors)
• Combination approaches

Substrate Reduction Therapy (SRT)

SRT aims to reduce HS production to match residual clearance capacity[@neuberger2018]:

• Small molecule inhibitors of HS synthesis
• Currently in preclinical/clinical development
• Potential for broader CNS effects

Adjunctive Therapies

| Approach | Target | Status |
|----------|--------|--------|
| Anti-inflammatory drugs | Neuroinflammation | Investigational |
| Antioxidants | Oxidative stress | Supportive care |
| Physical therapy | Motor function | Standard care |
| Behavioral interventions | Behavioral symptoms | Standard care |

Expression and Localization

Tissue Distribution

HGSNAT is expressed ubiquitously, with highest levels in:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High |
| Liver | High |
| Lung | High |
| Kidney | Moderate |
| Spleen | Moderate |
| Heart | Low |

Cellular Localization

In the brain, HGSNAT is expressed in:

• Neurons (particularly in [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus))
• [Astrocytes](/cell-type- [Oligodendrocytes](/cell-types/oligodendrocytes)lia
• [Oligodendrocytes](/cell-types/oligodendrocytes) Vascular endothelial cells

Pathophysiology

Mechanisms of Neurodegeneration

The neurodegeneration in MPS IIIC results from multiple interconnected mechanisms[@martson2020]:

Lysosomal dysfunction:

• Accumulation of undegraded HS
• Impaired lysosomal acidification
• Disrupted autophagic flux

• Endoplasmic reticulum stress
• Oxidative stress
• Mitochondrial dysfunction

• Microglial activation
• Astrocyte reactivity
• Elevated inflammatory cytokines

• Impaired synaptic plasticity
• Altered neurotransmitter signaling
• Dendritic spine abnormalities

Animal Models

Several model systems have been developed:

• Knockout mice: Recapitulate MPS IIIC phenotype
• iPSC-derived neurons: Patient-specific models
• Zebrafish models: Developmental studies
• Organoid systems: Brain modeling

Genetics

Mutation Spectrum

Over 100 pathogenic HGSNAT variants have been identified[@beesley2011]:

| Mutation Type | Frequency | Examples |
|--------------|-----------|----------|
| Missense | 45% | p.R374C, p.G375R |
| Nonsense | 25% | p.R236, p.W579 |
| Frameshift | 20% | c.1053delC, c.1843insG |
| Splice site | 10% | c.2143-1G>A |

Genotype-Phenotype Correlation

• Null mutations typically cause severe phenotype
• Missense mutations with residual activity may have milder disease
• No clear correlation between specific mutation and behavioral phenotype

Carrier Testing and Prenatal Diagnosis

• Carrier testing available for at-risk families
• Prenatal diagnosis possible through mutation analysis
• Newborn screening being implemented in some regions

Research Directions

Biomarker Development

Biomarkers for tracking disease progression and treatment response include[@raiman2017]:

• Urinary HS and HS-derived oligosaccharides
• CSF biomarkers (neurofilament light chain, β-amyloid, tau)
• Neuroimaging markers (brain volume, white matter integrity)
• Behavioral and cognitive assessments

Clinical Trials

Several therapeutic approaches are in development:

| Therapy | Phase | Mechanism |
|---------|-------|-----------|
| AAV-HGSNAT (intracranial) | Phase I/II | Gene replacement |
| Small molecule SRT | Preclinical | Reduce HS synthesis |
| Enzyme enhancement | Preclinical | Increase residual activity |

Broader Research Applications

Studying HGSNAT provides insights into:

• Lysosomal biology and autophagy
• HS metabolism in neural development and disease
• Mechanisms of neurodegenerative diseases
• Gene therapy for CNS disorders

Cross-Links

• [Lysosomal Storage Disorders](/mechanisms/lysosomal-storage-diseases)
• [Mucopolysaccharidoses](/diseases/lysosomal-storage-disorders)
• [Heparan Sulfate Proteoglycans](/proteins/heparan-sulfate-proteoglycans)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-parkinsons)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving HGSNAT Gene discovered through SciDEX knowledge graph analysis: